PIRAMAL PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149.8 INR | +0.47% |
|
+1.25% | +7.92% |
| May. 14 | Jefferies Adjusts Piramal Pharma’s Price Target to INR180 From INR170, Keeps at Buy | MT |
| May. 13 | Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024 |
Valuation
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 81,683 | 198,244 | - | - |
| Enterprise Value (EV) 1 | 129,493 | 170,528 | 235,047 | 229,235 |
| P/E ratio | -43.6 x | 921 x | 84.5 x | 35 x |
| Yield | - | 0.13% | 0.2% | 0.4% |
| Capitalization / Revenue | 1.15 x | 2.09 x | 2.15 x | 1.89 x |
| EV / Revenue | 1.83 x | 2.09 x | 2.55 x | 2.19 x |
| EV / EBITDA | 20.6 x | 14.3 x | 17 x | 12.7 x |
| EV / FCF | -28.1 x | 86.6 x | 42.3 x | 33.8 x |
| FCF Yield | -3.56% | 1.15% | 2.36% | 2.96% |
| Price to Book | 1.21 x | 2.5 x | 2.43 x | 2.3 x |
| Nbr of stocks (in thousands) | 1,193,319 | 1,322,948 | - | - |
| Reference price 2 | 68.45 | 149.8 | 149.8 | 149.8 |
| Announcement Date | 5/24/23 | 5/10/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 70,816 | 81,712 | 92,166 | 104,759 |
| EBITDA 1 | - | 6,282 | 11,963 | 13,852 | 18,028 |
| EBIT 1 | - | -484.5 | 4,557 | 5,941 | 9,658 |
| Operating Margin | - | -0.68% | 5.58% | 6.45% | 9.22% |
| Earnings before Tax (EBT) 1 | - | -1,202 | 1,793 | 3,739 | 8,388 |
| Net income 1 | 3,760 | -1,865 | 178.2 | 2,325 | 5,650 |
| Net margin | - | -2.63% | 0.22% | 2.52% | 5.39% |
| EPS 2 | 3.190 | -1.570 | 0.1400 | 1.773 | 4.280 |
| Free Cash Flow 1 | - | -4,612 | 2,678 | 5,556 | 6,778 |
| FCF margin | - | -6.51% | 3.3% | 6.03% | 6.47% |
| FCF Conversion (EBITDA) | - | - | 23.98% | 40.11% | 37.59% |
| FCF Conversion (Net income) | - | - | 227.38% | 239.02% | 119.96% |
| Dividend per Share 2 | - | - | 0.2000 | 0.3000 | 0.6000 |
| Announcement Date | 5/24/22 | 5/24/23 | 5/10/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Marzo | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 17,160 | 21,636 | 17,488 | 19,257 | 20,066 | 24,784 |
| EBITDA 1 | - | 873.3 | 3,513 | 1,323 | 2,232 | 3,011 | 4,498 |
| EBIT 1 | - | -771 | 1,669 | -412.9 | 498 | 1,307 | 3,099 |
| Operating Margin | - | -4.49% | 7.71% | -2.36% | 2.59% | 6.51% | 12.5% |
| Earnings before Tax (EBT) 1 | - | -736.4 | 948.9 | -1,071 | 348 | 1,067 | 2,761 |
| Net income 1 | -373.4 | -901.8 | 501.1 | -985.8 | 24.5 | 832.3 | 1,970 |
| Net margin | - | -5.26% | 2.32% | -5.64% | 0.13% | 4.15% | 7.95% |
| EPS | -0.3100 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/9/22 | 2/8/23 | 5/24/23 | 8/3/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: Marzo | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 47,810 | 33,704 | 36,803 | 30,991 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 7.61 x | 3.018 x | 2.657 x | 1.719 x |
| Free Cash Flow 1 | - | -4,612 | 2,678 | 5,557 | 6,778 |
| ROE (net income / shareholders' equity) | - | -2.76% | 1.76% | 2.9% | 6.75% |
| ROA (Net income/ Total Assets) | - | -1.69% | - | - | - |
| Assets 1 | - | 110,312 | - | - | - |
| Book Value Per Share 2 | - | 56.80 | 59.90 | 61.80 | 65.20 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 9,648 | 7,600 | 7,227 | 7,259 |
| Capex / Sales | - | 13.62% | 9.37% | 7.84% | 6.93% |
| Announcement Date | 5/24/22 | 5/24/23 | 5/10/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
149.8
INR
Average target price
176
INR
Spread / Average Target
+17.45%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.92% | 2.36B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- PPLPHARMA Stock
- Financials Piramal Pharma Limited